Processa Stock Analysis

PCSA -  USA Stock  

USD 3.55  0.16  4.31%

The big decline in price over the last few months for Processa Pharmaceuticalsmay encourage investors to take a closer look at the company as it is trading at a share price of 3.55 on very low momentum in trading volume. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in December. However, diversifying your holdings with Processa Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.91. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Processa Pharmaceuticals partners.
Please check Your Equity Center.

Processa Stock Analysis 

 
Refresh
The Processa Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Processa Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Processa Stock analysis module also helps to analyze the Processa Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Processa Stock Analysis Notes

About 31.0% of the company outstanding shares are owned by corporate insiders. The book value of Processa Pharmaceuticals was at this time reported as 1.74. The company recorded a loss per share of 1.54. Processa Pharmaceuticals had not issued any dividends in recent years. The entity had 1-7 split on the 23rd of December 2019. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Processa Pharmaceuticals contact David Young at 443 776 3133 or learn more at https://www.processapharmaceuticals.com.

Processa Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Processa Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Processa Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Processa Pharmaceuticals generated a negative expected return over the last 90 days
Processa Pharmaceuticals has high historical volatility and very poor performance
Processa Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (22.6 M) with profit before overhead, payroll, taxes, and interest of 5 K.
Processa Pharmaceuticals currently holds about 19.09 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Roughly 31.0% of the company outstanding shares are owned by corporate insiders
Latest headline from simplywall.st: Were Not Very Worried About Processa Pharmaceuticals Cash Burn Rate - Simply Wall St

Processa Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 58.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Processa Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Processa Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (38.49) % which means that it has lost $38.49 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (109.84) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals management efficiency ratios could be used to measure how well processa pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of January, Processa Pharmaceuticals holds the coefficient of variation of (437.65), and Risk Adjusted Performance of (0.18). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Processa Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Processa Pharmaceuticals, which can be compared to its competitors. Please check Processa Pharmaceuticals treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Processa Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 3.55 per share. Given that Processa Pharmaceuticals has jensen alpha of (0.84), we recommend you to check out Processa Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Processa Pharmaceuticals Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Simple Moving Average indicator is calculated by adding the closing price of Processa Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Processa Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Processa Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Processa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Floyd Robert Michael over two weeks ago via Macroaxis 
Acquisition by Floyd Robert Michael of 6722 shares of Processa Pharmaceuticals subject to Rule 16b-3
Floyd Robert Michael over two weeks ago via Macroaxis 
Acquisition by Floyd Robert Michael of 6722 shares of Processa Pharmaceuticals subject to Rule 16b-3
Patrick Lin over a month ago via Macroaxis 
Purchase by Patrick Lin of 3000 shares of Processa Pharmaceuticals
Patrick Lin over a month ago via Macroaxis 
Purchase by Patrick Lin of 3500 shares of Processa Pharmaceuticals
Floyd Robert Michael over three months ago via Macroaxis 
Processa Pharmaceuticals exotic insider transaction detected
Floyd Robert Michael over three months ago via Macroaxis 
Acquisition by Floyd Robert Michael of 6024 shares of Processa Pharmaceuticals subject to Rule 16b-3
David Young over three months ago via Macroaxis 
Acquisition by David Young of 8127 shares of Processa Pharmaceuticals subject to Rule 16b-3
Justin Yorke over three months ago via Macroaxis 
Processa Pharmaceuticals exotic insider transaction detected
Patrick Lin over three months ago via Macroaxis 
Purchase by Patrick Lin of 4000 shares of Processa Pharmaceuticals
Pannu Geraldine over three months ago via Macroaxis 
Acquisition by Pannu Geraldine of 1169 shares of Processa Pharmaceuticals subject to Rule 16b-3
Floyd Robert Michael over six months ago via Macroaxis 
Acquisition by Floyd Robert Michael of 1907 shares of Processa Pharmaceuticals subject to Rule 16b-3
David Young over six months ago via Macroaxis 
Processa Pharmaceuticals exotic insider transaction detected

Processa Pharmaceuticals Technical and Predictive Indicators

Processa Pharmaceuticals Forecast Models

Processa Pharmaceuticals time-series forecasting models is one of many Processa Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Processa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Processa Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Processa Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Processa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Processa Pharmaceuticals. By using and applying Processa Stock analysis, traders can create a robust methodology for identifying Processa entry and exit points for their positions.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Processa Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module
Please check Your Equity Center. Note that the Processa Pharmaceuticals information on this page should be used as a complementary analysis to other Processa Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Processa Stock analysis

When running Processa Pharmaceuticals price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is Processa Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Processa Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.